Kornimate/medical-research-clean huggingface dataset:
endocervical evaluation with the curette versus cytobrush for the diagnosis of dysplasia of the uterine cervix

Conditions: Cervical Dysplasia

Summary: objective: to compare endocervical brushing with endocervical curettage with respect to diagnostic and patient discomfort. method: women referred to colposcopy because of abnormal papanicolaou tests will be randomized to endocervical sampling with either a metal curette (endocervical curettage -ecc) or and endocervical brush. all samples will be submitted for histological study.


Eligibility criteria:
inclusion criteria: * french-speaking * 21 years or older * attending our colposcopy clinic * need for endocervical evaluation * full autonomy or capacity to understand the procedures exclusion criteria: * pregnancy * absence of uterus * history of des exposure in utero
ultrasound in treating patients with prostate cancer confined to the prostate

Conditions: Prostate Cancer

Summary: rationale: highly focused ultrasound energy may be able to kill cancer cells by heating the tumor without affecting the surrounding tissue. purpose: phase i trial to study the effectiveness of focused ultrasound energy in treating patients who have prostate cancer that has not spread beyond the prostate.

objectives: * determine the ability of sonablate to focus ultrasonic waves for the purpose of selectively destroying prostate cancer tissue, with resultant drop in psa levels to below 0.5 ng/ml and negative biopsy for cancer cells, in patients with organ-confined prostate cancer. outline: this is a multicenter study. a probe is inserted into the rectum. high-intensity focused ultrasound (hifu) energy using the sonablate system is delivered to the prostate tissue over approximately 2-3 hours. patients with residual cancer lesion (by biopsy), psa greater than 0.5 ng/ml or increasing psa levels taken at least 2 months apart, visible prostate tissue on ultrasound, and no local or distant metastases after day 90 undergo retreatment with hifu. patients are followed at 2, 14, 30, 90, and 180 days. projected accrual: a total of 20 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed organ-confined prostate cancer (clinical stage t1 or t2 only) * pretreatment prostate weight less than 40 g * gleason score no greater than 7 * psa no greater than 10 ng/ml * no significant intravesical median lobe (greater than 2 cm) on ultrasound * able to visualize prostate gland adequately on transrectal ultrasound imaging * no prostate calcification greater than 5 mm * no metastases by bone scan patient characteristics: age: * 40 to 80 performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * no bleeding disorder as determined by abnormal pt and ptt renal: * no active urinary tract infection * no history of urinary bladder neck contracture other: * no prior allergy to latex * no anesthesia surgical assignment category iv or greater * no interest in future fertility * no history of inflammatory bowel disease * no other concurrent major debilitating illness * no other prior or concurrent malignancy except skin cancer prior concurrent therapy: biologic therapy: * no prior biologic therapy for prostate cancer chemotherapy: * no prior chemotherapy for prostate cancer endocrine therapy: * at least 3 months since prior hormonal therapy (including finasteride) for prostate cancer radiotherapy: * no prior radiotherapy for prostate cancer surgery: * no prior transurethral resection of prostate * no prior urethral stent * no prior major rectal surgery other: * no prior cryotherapy for prostate cancer * no prior thermotherapy * no other prior therapy for prostate cancer * no concurrent warfarin or other anticoagulant

Keywords: stage i prostate cancer stage iib prostate cancer stage iia prostate cancer
prospective observational study to describe characteristics and management of patients treated with denosumab (prolia®) in routine clinical practice

Conditions: Osteoporosis, Postmenopausal

Summary: the objective of this prospective, observational study in czech republic and slovakia is to describe per country the characteristics of women treated with denosumab in routine clinical practice and the clinical management of these patients during the first 2 years of treatment. in addition, the study aims to collect safety data in the real-life clinical practice settings on adverse drug reactions (adrs) and serious adrs.


Eligibility criteria:
inclusion criteria * women with a clinical diagnosis of postmenopausal osteoporosis * decision has been made to treat with denosumab 60 mg once every 6 months * have received their first injection of denosumab within 8 weeks prior to enrolling in this study. * appropriate written informed consent has been obtained (as required per local country regulations) exclusion criteria * participating in ongoing or have participated in previous denosumab clinical trials * participation in other clinical or device trials in the last 6 months * contra-indicated for treatment with prolia® according to the approved applicable local product label. * subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent
circulating ghrelin as a biomarker for dementia

Conditions: Dementia

Summary: the primary objective of this study will explore whether circulating acyl-ghrelin (ag) and unacylated-ghrelin (uag) are reduced in neurodegenerative disease associated with cognitive impairment. it will focus on validating pilot data generated following the analysis of parkinson's disease (pd), parkinson's disease dementia (pdd) and healthy cohorts (iras project id: 250933). in addition to the advantages of study replication we will extend the analysis to include two further patient groups that are associated with cognitive impairments, namely, alzheimer's dementia (ad) and dementia with lewy bodies (dlb). this study will increase confidence in the replication of our findings. this will be a cross-sectional study using peripheral venous blood.


Eligibility criteria:
inclusion criteria: * age \> 60 years * subject or carer / legal representative is willing to sign consent document specific criteria for each group; parkinson's disease * pd diagnosed by a movement disorder specialist and meets the diagnosis of pd * moca \> 26/30 * no evidence of cognitive symptoms causing functional impairment parkinson's disease dementia * pd diagnosed by a movement disorder specialist * duration of motor symptoms \> 1 year * meets mds task force criteria for pdd * moca \< 21/30 dementia with lewy bodies * meets criteria for probable dlb as defined by the 4th report of the dlb consortium alzheimer's disease * meets criteria for probable ad dementia (consistent with nia/aa core clinical criteria for probable ad dementia) exclusion criteria: * age \< 60 years * current major depression * use of anti-psychotic medication * type i or type ii diabetes mellitus (dm) (excluding diet-controlled dm) * tobacco use * bmi \<15.0 kg/m2 * bmi \> 30 kg/m2 * comorbid gastrointestinal disease i.e. includes coeliac, active inflammatory bowel disease (colitis), evidence for active gastric ulcers within the last 12 months, but excludes gastroesophageal reflux and hiatus hernia. * \>5 kg weight change over the preceding 3 months (determined by researcher from previous clinic visit and discussion with partner/carer) * significant active comorbidity * difficult venous access * vagotomy additional disease specific exclusions; * parkinson's disease exclusion criteria * evidence of dementia or mild cognitive impairment * deep brain stimulation (dbs) * use of duodopa parkinson's disease dementia exclusion criteria * dementia within 12 months of diagnosis of pd * dbs dementia with lewy bodies exclusion criteria * onset of motor parkinsonism symptoms greater than 12 months prior to dementia diagnosis alzheimer's dementia exclusion criteria * presence of pd, pdd, dlb, or frontotemporal dementia (ftd) controls exclusion criteria * evidence of parkinsonism * evidence of dementia or mild cognitive impairment * moca \<26/30
the effectiveness of calistenic exercise training in adolescents

Conditions: Adolescent Development

Summary: objective: the aim of this study is to examine the effectiveness of calisthenic exercise training applied via video chat application on physical activity, physical fitness, quality of life and sleep, and anxiety and depression levels in adolescents during distance education. material and methods: in our study, 38 adolescents were randomly divided into two equal groups as exercise training group and control group. calisthenic exercise training was given to the exercise training group for eight weeks, three days a week, via video chat application and under the supervision of a physiotherapist. the control group was evaluated before and after the study period. physical activity levels of individuals; international physical activity scale, quality of life; children's quality of life scale, anxiety depression levels; beck anxiety scale, reynolds depression scale and sleep quality were evaluated with pittsburg sleep quality index.


Eligibility criteria:
inclusion criteria: * healthy adolescent children exclusion criteria: * individuals with a disease that could prevent them from doing our exercise training were not included in the study.

Keywords: adolescent teleconference exercise training calisthenic exercise physical activity
suction cervical stabilizer compared to standard tenaculum for intrauterine procedures

Conditions: Intrauterine Device (IUD); Abnormal Uterine Bleeding

Summary: to evaluate patient-reported pain, bleeding, and device efficiency along with provider satisfaction and ease of use between intrauterine procedures employing a suction cervical stabilizer (new device, fda approved, atraumatic) or single-tooth tenaculum (standard, traumatic). this device, cleared by the fda in 2023, was studied in europe and showed pain reduced by up to 73% and bleeding reduced by 78% compared to the single-tooth tenaculum for intrauterine contraceptive device insertion. the investigators seek to study this device in the united states, and trial it among all intrauterine procedures.


Eligibility criteria:
inclusion criteria: * • age 18 years or older * speaks and reads in english * able to consent on their own * will undergo any intrauterine procedure using the carevix (for exposure group) or using tenaculum (for control group) * cervix at least 26 mm in diameter * twenty providers performing this procedure exclusion criteria: * • vaginal bleeding of unknown origin * cervix less than 26 mm in diameter * nabothian cyst on anterior lip of cervix * cervical myomas * cervical abnormalities * pregnant
feno after hypoxia in asthma patients

Conditions: Asthma

Summary: stable asthma patients (gina 1-2) stay 6 days in a row for 4 hours per day in a hypoxic chamber simulating 2800m above sea level. study participants will be blinded to the treatment given and divided into a hypoxic and a sham group (about 360m above sea level). effects of this intermittent hypoxia on the asthmatic inflammation of these patients will be measured. the primary endpoint is the change in forced exhaled nitric oxide (feno) before and after the study. secondary endpoints include blood parameters, lung function testing and questionnaires.


Eligibility criteria:
inclusion criteria: * stable asthma (gina 1-2) exclusion criteria: * autoimmune disease * unstable asthma (gina 3-4) * history of pneumonia/fever within 3 months * place of residence \>1000m above sea level * trip/vacation above \>2500m within 4 weeks * cystic fibrosis * diabetes mellitus * immunodeficiency * atopic dermatitis * ciliary dyskinesia * pregnancy * chronic obstructive pulmonary disease * history of smoking (\>1py) * immunosuppression / systemic corticosteroids within 3 months * cardiovascular diseases * interstitial lung disease * bronchopulmonary dysplasia

Keywords: asthma hypoxia forced exhaled nitric oxide inflammation
a study to evaluate bms-986141 added on to aspirin or ticagrelor or the combination, on thrombus formation in a thrombosis chamber model in participants with stable coronary artery disease and healthy participants

Conditions: Coronary Artery Disease; Healthy Participants

Summary: the purpose of this study is to assess the effectiveness, safety and tolerability of bms-986141 added on to aspirin or ticagrelor or the combination on thrombus formation in both healthy participants and participants with stable coronary artery disease.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit: www.bmsstudyconnect.com inclusion criteria: * male or female between 18 to 75 years of age, inclusive, and body mass index (weight kg/m2) between 18 and 35 kg/m2 (inclusive), and body weight 50 kg and 120 kg (inclusive) * judged to be generally in good health based on medical history, physical examination, ecgs, vital signs and laboratory tests * signed an informed consent document indicating they understand the purpose of and procedures required for the experiment and are willing to participate in the experiment * willing/able to adhere to the visit schedule * for treatment arms groups with stable cad participants (not for healthy volunteers without cad) one or more of: prior angiographically proven cad (\>50% stenosis of proximal coronary artery), prior coronary revascularization (pci or cabg), prior myocardial infarction (mi) exclusion criteria: * participants who meet any of the following criteria will be excluded from participating in the experiment: allergies or intolerance of aspirin, ticagrelor and bms-986141, requirement for dual antiplatelet therapy, requirement for anticoagulant therapy * acute coronary syndrome or coronary revascularization within 3 months * coagulation disorders (including any abnormal bleeding or blood dyscrasias), anemia, renal or hepatic insufficiency or any others illness that the investigator considers should exclude the participants/patients of that could interfere with the interpretation to the results * acute illness, including a common cold, within 7 days prior to visit or other significant acute or chronic medical illness * major or traumatic surgery within 12 weeks of screening * history of, a reason to believe that, a blood donor subject has a history of drug or alcohol abuse within the past 5 years or has not abstained from alcohol for at least 24 hours prior to visit * positive serum or urine pregnancy test * not anatomically suitable for or unwilling to undergo venipunctures * participation in a study of an investigational medicinal product within the last 4 weeks * any condition that, in the opinion of the investigator, would compromise the wellbeing of the blood donor subject or the experiment or prevent the blood donor subject from meeting or performing experiment requirements other protocol-defined inclusion/exclusion criteria apply

Keywords: thrombosis coronary artery disease healthy participants aspirin ticagrelor brilinta bms-986141
oxygen extraction-guided transfusion

Conditions: Blood Transfusion

Summary: in critically ill patients, optimized strategies for red blood cells transfusion (rbct) are still controversial. most recent guidelines suggest that clinical practice in icu setting should follow a restrictive approach to rbct (i.e., hemoglonim level \< 7.0 g/dl).in our previous study, oxygen extraction ratio (o2er) has shown good performance as a marker to identify the correct timing for rbct, potentially affecting 90-day mortality in non-bleeding, critically ill patients \[11\]. moreover, our data suggested that an individualized strategy for rbct may reduce the incidence of acute kidney injury (aki), which is possibly related to a better delivery of oxygen and organ perfusion.


Eligibility criteria:
inclusion criteria: * hb levels ≤ 9.0 g/dl (as confirmed through a blood test and/or through blood gas analysis) * presence of an arterial line and a central venous line (either jugular or subclavian), with confirmed correct position of the catheter tip at the atrio-caval junction (allowing correct estimation of central venous saturation, scvo2). exclusion criteria: * age \< 18 years; * pregnancy * clinical evidence of acute bleeding * diagnosis of haematological malignancy * diagnosis of sickle cell disease, or other diseases exposing the patient to chronic rcbts * acquired or congenital disorders of coagulation * patients with ongoing aki of stage 1 or worse and/or known chronic kidney disease (ckd) of stage g3a or worse, defined as glomerular filtration rate below 60 for a minimum of 3 months
efficacy study of pad and tad in newly diagnosed multiple myeloma

Conditions: Multiple Myeloma

Summary: the primary purpose of this study is to evaluate the efficacy of pad-regimen and tad-regimen in newly diagnosed multiple myeloma(mm).

multiple myeloma (mm) is a malignant tumor with abnormal proliferation of monoclonal plasma cells in bone marrow. bone damage is one of the characteristic clinical manifestations. myeloma plasma cells and bone marrow microenvironment are the targets of thalidomide and bortezomib. the regimens based on them as first-line treatments of mm have greatly improved efficacy and prolonged the survival of mm patients. but whether the regimens can prevent and treat bone complications of mm patients or improve the quality of life is not clear. by evaluating the efficacy of pad-regimen(bortezomib,pirarubicin and dexamethasone) and tad-regimen(thalidomide,pirarubicin and dexamethasone) in mm and the effect of them on bone lesions, this study can provide evidence of evidence-based medicine for mm treatment.

Eligibility criteria:
inclusion criteria: * subjects with symptomatic and measurable newly diagnosed multiple myeloma. * age \> 18 years, kps ≥ 60, and life expectancy of at least 3 months. * subjects must meet all of the following criteria within 14 days before starting therapy: plt≥50×109/l, hb≥70 g/l, anc≥0.75×109/l * subjects (or their legally acceptable representatives) must signed an informed consent document. exclusion criteria: * severe cardiovascular disease ; hiv infection, or positive hbsag, or active hepatitis c; hbv-dna\>104; hepatic functional parameter\>2.5 times the upper limit of institutional laboratory normal. * grade 2 or more severe peripheral neuropathy or neuropathic pain; grade 2 or more severe impaired hepatic and kidney function. * patient has radiotherapy or major surgery within 30 days before enrollment. * patient has hypersensitivity to boron, mannitol or thalidomide. * pregnant or breastfeeding women, or subject unwilling to use a method for contraception during the study.

Keywords: bortezomib,thalidomide,bone metabolites
efficacy of balance training by bbs on gait parameters and balance in patients with rlas

Conditions: Ankle Sprains

Summary: this study will be conducted to find out the effect of adding balance training on gait parameters, balance, and sensory interaction

las are not benign injuries. as many as 4 in 10 individuals will develop chronic ankle instability (cai) after a first-time sprain, more than half of patients with osteoarthritis (oa) of the ankle report a history of a sport-related ankle injury, and 85% of those are las.

Eligibility criteria:
inclusion criteria: * the patient will be referred to the outpatient clinic of the orthopedic department, faculty of physical therapy, mti university. with a confirmed diagnosis of recurrent lateral ankle sprain grade ii * subjects will be excluded if they had one of the following criteria: previous musculoskeletal injury to the lower limb or lumbar spine including a fracture, a sprain, or an unstable joint other than the injured ankle.
angiojet thrombectomy and stenting for treatment of acute myocardial infarction

Conditions: Myocardial Infarction

Summary: the purpose of this study is to determine whether prompt removal of thrombus (blood clot) from a blocked coronary artery using the angiojet rheolytic thrombectomy device will result in improved blood flow within the heart and a smaller final infarct size (reduced injury to the heart muscle).

occlusive thrombosis triggered by a disrupted or eroded atherosclerotic plaque is the anatomic substrate of most acute myocardial infarctions (ami). macro- and microembolization of thrombus during percutaneous coronary intervention (pci) in ami is frequent and may result in obstruction of the microvessel network, and decreased efficacy of reperfusion and myocardial salvage. direct stenting without predilation or postdilation is the most simplistic approach to the problem of embolization, and may decrease embolization and the incidence of the no-reflow phenomenon. other approaches to the problem of microvessel embolization include percutaneous rheolytic thrombectomy (rt) with the angiojet catheter before stent implantation. the objectives of the study are: to assess whether rt before direct infarct artery stenting results in improved reperfusion success in patients with acute st-segment elevation myocardial infarction (stemi) and angiographically evident thrombus; and to validate a technique for use of the angiojet rt catheter in the treatment of stemi. comparisons: treatment with angiojet rt immediately before direct infarct artery stenting versus direct stenting alone, in patients with stemi and angiographically visible thrombus presenting within 6 hours of symptom onset for primary pci.

Eligibility criteria:
inclusion criteria: * patient age \> 18 years * st-segment elevation myocardial infarction * angiographically visible thrombus * presentation within 6 hours of symptom onset for primary percutaneous coronary intervention * patient, or relative or legal guardian,provides written informed consent * patient has no childbearing potential or is not pregnant exclusion criteria: * prior administration of thrombolysis for current mi * participation in another study * major surgery within past 6 weeks * history of stroke within 30 days, or any history of hemorrhagic stroke * severe hypertension (systolic bp \> 200 mm hg or diastolic bp \> 110 mm hg) not controlled on antihypertensive therapy * known neutropenia ( \<1000 neutrophils per mm3) or known severe thrombocytopenia (\< 50,000 platelets per mm3) * known prior history of renal insufficiency * co-morbidities with expected survival \< 1 year * patient unwilling to receive blood products

Keywords: coronary thrombectomy thrombectomy for acute myocardial infarction c14.280.647.500 c14.907.553.355.500